Company news
Jacobio Pharmaceuticals Group Co., Ltd. (HKEX:1167) news
Jacobio Pharmaceuticals Group Co., Ltd. news releases on 6ix. Latest, Mar 10, 2026: Jacobio Announces 2025 Annual Results
Press releases & updates
Jacobio Announces 2025 Annual Results
March 10, 2026
Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73
December 21, 2025
Jacobio Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International Conference
October 23, 2025
Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline
October 15, 2025
Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
September 24, 2025
Jacobio Pharma Announces 2025 Interim Results
August 29, 2025
Jacobio's IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted
July 1, 2025
Jacobio Pharma Announces 2024 Annual Results
March 19, 2025
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China
August 30, 2024
Jacobio Pharma Announces 2022 Annual Results
March 22, 2023
Jacobio Pharmaceuticals : VOLUNTARY ANNOUNCEMENT JACOBIO ANNOUNCES THE FIRST PATIENT DOSED IN CLINICAL TRIAL OF KRAS G12C JAB-21822 IN CHINA
August 3, 2021
Jacobio Pharmaceuticals : VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVES US FDA INVESTIGATIONAL NEW DRUG CLEARANCE FOR KRAS G12C INHIBITOR
May 2, 2021
Jacobio Pharmaceuticals : RESIGNATION OF PRESIDENT OF RESEARCH AND DEVELOPMENT AND APPOINTMENT OF CHIEF BIOLOGIST
April 30, 2021
Jacobio Pharmaceuticals : PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING
April 22, 2021
Jacobio Pharmaceuticals : ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020 CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE UNDER THE LISTING RULES AND AUTHORISED REPRESENTATIVE UNDER THE HONG KONG COMPANIES ORDINANCE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
March 26, 2021